Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

University of Miami

Status and phase: Completed; Phase 2

Conditions: Aging; Skin Abnormalities

Treatments: Drug: Polypodium leucotomos

Study type: Interventional

Funder types: Other

Identifiers

NCT00520910

20070203

Details and patient eligibility

About

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects,
• 18 years of age or older,
• with Fitzpatrick skin types II and III.

Exclusion criteria

• Pregnancy
• Personal history of skin cancer
• History of abnormal photosensitivity
• Smokers
• Patients with history or being exposed to other forms of radiation (other than sunlight)
• History or current exposure to asbestos
• Patients taking any drug that might alter the response of skin to UVR (including, but are not limited to, doxycycline, sulfas, psoralens, and amiodarone)
• Patients unable to undergo skin biopsies
• History of abnormal scarring
• History of adverse reaction to local anesthesia

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

10 participants in 2 patient groups

Polypodium leucotomos extract

Experimental group

Description:

Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.

Treatment:

Drug: Polypodium leucotomos

No intervention

No Intervention group

Description:

Subject is not given any treatment.